ELI LILLY & Co
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1410.99−6.55 (-0.46%)
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Deferred tax assets — Capitalized R&D & IPR&D by Year
Deferred tax assets — Capitalized R&D & IPR&D ($M) ($M)
Eli Lilly Deferred tax assets — Capitalized R&D & IPR&D: $4,518M in FY2025, down 1.8% from a year earlier.
Latest, FY2025
4,518
Period ended Dec 31, 2025
Change on a year earlier
-1.8%
4,599 in FY2024
History
7 years
Since FY2019
Sources
6
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-12) ↗
Reported in Form 10-K Note 13 Income Taxes.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Deferred tax assets — Capitalized R&D & IPR&D ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4,518 | -1.8% | Form 10-K (filed 2026-02-12) ↗ |
| FY2024 | Dec 31, 2024 | 4,599 | +53.4% | Form 10-K (filed 2026-02-12) ↗ |
| FY2023 | Dec 31, 2023 | 2,998 | +85.6% | Form 10-K (filed 2025-02-19) ↗ |
| FY2022 | Dec 31, 2022 | 1,615 | +487.2% | Form 10-K (filed 2024-02-21) ↗ |
| FY2021 | Dec 31, 2021 | 275 | +103.5% | Form 10-K (filed 2023-02-22) ↗ |
| FY2020 | Dec 31, 2020 | 135 | +78.6% | Form 10-K (filed 2022-02-23) ↗ |
| FY2019 | Dec 31, 2019 | 75.7 | – | Form 10-K (filed 2021-02-17) ↗ |
Cite this data
StockData. (2026). Eli Lilly Deferred tax assets — Capitalized R&D & IPR&D ($M), annual FY2019–FY2025 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/dta-iprd
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.